More about

Diabetes

News
November 11, 2024
2 min read
Save

Exacerbation, hospitalization rates smaller with use vs. no use of metformin in COPD

Exacerbation, hospitalization rates smaller with use vs. no use of metformin in COPD

BOSTON — Among adults with COPD, the odds for exacerbations and hospitalizations were elevated in patients who did not use vs. did use the diabetes medication metformin, according to an abstract presented at the CHEST Annual Meeting.

News
November 07, 2024
2 min read
Save

Top in women’s health: GLP-1s may curb fibroid risk; home ovulation kits equally effective

Top in women’s health: GLP-1s may curb fibroid risk; home ovulation kits equally effective

Researchers found that women with type 2 diabetes who received at least two doses of GLP-1 receptor agonists had a 27% lower risk for developing new-onset uterine fibroids compared to those who use metformin or insulin.

News
November 06, 2024
1 min read
Save

Glucagon-like peptide-1 agonists may be safe for patients with diabetes undergoing THA

Glucagon-like peptide-1 agonists may be safe for patients with diabetes undergoing THA

According to published results, glucagon-like peptide-1 agonists may not be associated with increased complications for patients with diabetes who undergo total hip arthroplasty.

News
November 06, 2024
3 min read
Save

Q&A: Time-restricted eating can have a 'meaningful impact' on metabolic syndrome

Q&A: Time-restricted eating can have a 'meaningful impact' on metabolic syndrome

Time-restricted eating can improve the health of individuals with metabolic syndrome, who are on the precipice of type 2 diabetes, heart disease and other health complications, according to an expert.

News
November 06, 2024
1 min read
Save

GLP-1 medication access limited by care site, payer type, demographics

GLP-1 medication access limited by care site, payer type, demographics

SAN ANTONIO — Access to GLP-1 medications is potentially impacted by care site, payer type and demographics, highlighting gaps in care that disproportionately affect certain patient subgroups, according to a presentation at ObesityWeek.

News
November 06, 2024
3 min read
Save

GLP-1 alternative well-tolerated, could lead to similar rate of weight loss

GLP-1 alternative well-tolerated, could lead to similar rate of weight loss

SAN ANTONIO — Petrelintide, a novel once-weekly amylin analog, was well-tolerated in a cohort of healthy people with overweight or obesity, while conferring up to 8.6% weight loss at 16 weeks, a speaker reported.

News
November 06, 2024
2 min read
Save

Retatrutide linked to improved health-related quality of life plus weight loss

Retatrutide linked to improved health-related quality of life plus weight loss

SAN ANTONIO — In patients with obesity, the novel triple receptor agonist retatrutide was associated with improvement in health-related quality of life vs. placebo, a speaker reported.

News
November 05, 2024
5 min read
Save

Tirzepatide safe, effective for weight loss, preventing diabetes progression at 3 years

Tirzepatide safe, effective for weight loss, preventing diabetes progression at 3 years

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but only so long as they continued the weight-loss medication, a speaker reported.

News
November 04, 2024
1 min read
Save

Semaglutide cuts major kidney complications risk for adults with type 2 diabetes, CKD

SAN DIEGO — Semaglutide was associated with lower risk for major kidney complications for adults with type 2 diabetes and chronic kidney disease without regard to baseline kidney function, data show.

News
November 04, 2024
3 min read
Save

Patient interviews help identify components to a successful GLP-1 weight-loss program

Patient interviews help identify components to a successful GLP-1 weight-loss program

SAN ANTONIO — Patient interviews showed weight loss via GLP-1 receptor agonists is a major emotional journey, many have anxiety surrounding cessation and weight regain due to lack of access, a speaker reported.

View more